Victor Navas Moreno, Fernando Sebastian-Valles, Miguel Sampedro-Nuñez, Marcos Lahera Vargas, Monica Marazuela, José Alfonso Arranz Martin
{"title":"成人1型糖尿病患者治疗6个月时三种先进混合闭环系统的患者满意度：一项随访研究。","authors":"Victor Navas Moreno, Fernando Sebastian-Valles, Miguel Sampedro-Nuñez, Marcos Lahera Vargas, Monica Marazuela, José Alfonso Arranz Martin","doi":"10.1016/j.endien.2023.06.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p><span>Advanced hybrid closed-loop (AHCL) systems have demonstrated improved glycemic control in individuals with </span>Type 1 Diabetes Mellitus<span>. The aim of this study is to compare patient satisfaction among three available AHCL systems (Medtronic Minimed780 G, Roche Diabeloop DBLG1, and Tandem t:slim X2 Control IQ) after six months of treatment and to determine if it is related to glycemic control.</span></p></div><div><h3>Methods</h3><p>The data of 75 individuals were analyzed, including 15 using the DBLG1 system, 9 using Control IQ, and 51 using MM780 G. Patient satisfaction was assessed using the Diabetes Treatment Satisfaction Questionnaire for Diabetes Mellitus (DTSQc), a validated instrument.</p></div><div><h3>Results</h3><p><span>All systems demonstrated treatment satisfaction. The DBLG-1 system scored 14 (−15–21) points, while Control IQ scored 21 (9–24) and M780 G scored 19 (11–24) (p = 0.004). The multivariate analysis revealed that the DBLG-1 system is associated with a lower DTSQc score (OR 0.19, p = 0.019) independent of glycemic control, sex, age, duration of diabetes, duration as an </span>insulin pump user, and daily insulin dose.</p></div><div><h3>Conclusion</h3><p>AHCL systems are satisfactory treatments for users, with potential variations observed between each system regardless of the achieved glycemic control.</p></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"70 8","pages":"Pages 548-555"},"PeriodicalIF":1.8000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Patient satisfaction in three advanced hybrid closed-loop systems at 6 months of treatment in adults with type 1 diabetes mellitus: a follow-up study\",\"authors\":\"Victor Navas Moreno, Fernando Sebastian-Valles, Miguel Sampedro-Nuñez, Marcos Lahera Vargas, Monica Marazuela, José Alfonso Arranz Martin\",\"doi\":\"10.1016/j.endien.2023.06.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p><span>Advanced hybrid closed-loop (AHCL) systems have demonstrated improved glycemic control in individuals with </span>Type 1 Diabetes Mellitus<span>. The aim of this study is to compare patient satisfaction among three available AHCL systems (Medtronic Minimed780 G, Roche Diabeloop DBLG1, and Tandem t:slim X2 Control IQ) after six months of treatment and to determine if it is related to glycemic control.</span></p></div><div><h3>Methods</h3><p>The data of 75 individuals were analyzed, including 15 using the DBLG1 system, 9 using Control IQ, and 51 using MM780 G. Patient satisfaction was assessed using the Diabetes Treatment Satisfaction Questionnaire for Diabetes Mellitus (DTSQc), a validated instrument.</p></div><div><h3>Results</h3><p><span>All systems demonstrated treatment satisfaction. The DBLG-1 system scored 14 (−15–21) points, while Control IQ scored 21 (9–24) and M780 G scored 19 (11–24) (p = 0.004). The multivariate analysis revealed that the DBLG-1 system is associated with a lower DTSQc score (OR 0.19, p = 0.019) independent of glycemic control, sex, age, duration of diabetes, duration as an </span>insulin pump user, and daily insulin dose.</p></div><div><h3>Conclusion</h3><p>AHCL systems are satisfactory treatments for users, with potential variations observed between each system regardless of the achieved glycemic control.</p></div>\",\"PeriodicalId\":48650,\"journal\":{\"name\":\"Endocrinologia Diabetes Y Nutricion\",\"volume\":\"70 8\",\"pages\":\"Pages 548-555\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2023-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Endocrinologia Diabetes Y Nutricion\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2530018023001348\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrinologia Diabetes Y Nutricion","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2530018023001348","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
摘要
引言：先进的混合闭环（AHCL）系统已证明改善了1型糖尿病患者的血糖控制。本研究的目的是比较三种可用AHCL系统（美敦力Minimed780G、罗氏Diabeloop DBLG1和Tandem t:slim X2 Control IQ）在治疗六个月后的患者满意度，并确定其是否与血糖控制有关。方法：对75名个体的数据进行分析，其中15名使用DBLG1系统，9名使用对照IQ，51名使用MM780G。使用经验证的糖尿病治疗满意度问卷（DTSQc）评估患者满意度。结果：所有系统均显示出治疗满意度。DBLG-1系统得分为14分（-15-21分），对照IQ得分为21分（9-24分），M780 G得分为19分（11-24分）（p=0.004分）。多变量分析显示，DBLG-1与较低的DTSQc得分（OR 0.19，p=0.019）相关，与血糖控制、性别、年龄、糖尿病持续时间、胰岛素泵使用者持续时间和每日胰岛素剂量无关。结论：AHCL系统是用户满意的治疗方法，无论血糖控制效果如何，每个系统之间都存在潜在的差异。
Patient satisfaction in three advanced hybrid closed-loop systems at 6 months of treatment in adults with type 1 diabetes mellitus: a follow-up study
Introduction
Advanced hybrid closed-loop (AHCL) systems have demonstrated improved glycemic control in individuals with Type 1 Diabetes Mellitus. The aim of this study is to compare patient satisfaction among three available AHCL systems (Medtronic Minimed780 G, Roche Diabeloop DBLG1, and Tandem t:slim X2 Control IQ) after six months of treatment and to determine if it is related to glycemic control.
Methods
The data of 75 individuals were analyzed, including 15 using the DBLG1 system, 9 using Control IQ, and 51 using MM780 G. Patient satisfaction was assessed using the Diabetes Treatment Satisfaction Questionnaire for Diabetes Mellitus (DTSQc), a validated instrument.
Results
All systems demonstrated treatment satisfaction. The DBLG-1 system scored 14 (−15–21) points, while Control IQ scored 21 (9–24) and M780 G scored 19 (11–24) (p = 0.004). The multivariate analysis revealed that the DBLG-1 system is associated with a lower DTSQc score (OR 0.19, p = 0.019) independent of glycemic control, sex, age, duration of diabetes, duration as an insulin pump user, and daily insulin dose.
Conclusion
AHCL systems are satisfactory treatments for users, with potential variations observed between each system regardless of the achieved glycemic control.
期刊介绍：
Endocrinología, Diabetes y Nutrición is the official journal of the Spanish Society of Endocrinology and Nutrition (Sociedad Española de Endocrinología y Nutrición, SEEN) and the Spanish Society of Diabetes (Sociedad Española de Diabetes, SED), and was founded in 1954.
The aim of the journal is to improve knowledge and be a useful tool in practice for clinical and laboratory specialists, trainee physicians, researchers, and nurses interested in endocrinology, diabetes, nutrition and related disciplines.
It is an international journal published in Spanish (print and online) and English (online), covering different fields of endocrinology and metabolism, including diabetes, obesity, and nutrition disorders, as well as the most relevant research produced mainly in Spanish language territories.
The quality of the contents is ensured by a prestigious national and international board, and by a selected panel of specialists involved in a rigorous peer review. The result is that only manuscripts containing high quality research and with utmost interest for clinicians and professionals related in the field are published.
The Journal publishes Original clinical and research articles, Reviews, Special articles, Clinical Guidelines, Position Statements from both societies and Letters to the editor.
Endocrinología, Diabetes y Nutrición can be found at Science Citation Index Expanded, Medline/PubMed and SCOPUS.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
